Newsfeeds Archive - Spark Newswire

3 minute read

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In

May 14, 1:32 PM

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.

ABBV

2 minute read

Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View

By Vandana Singh

April 30, 11:44 AM

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with adjusted EPS surpassing expectations.

HRMY

4 minute read

Analyst Ratings

Key Takeaways From Harmony Biosciences Analyst Ratings

By Benzinga Insights

April 30, 9:00 AM

Across the recent three months, 10 analysts have shared their insights on Harmony Biosciences (NASDAQ:HRMY), expressing a variety…

HRMY

2 minute read

Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist; Harmony Will Pay Bioprojet An Upfront License Fee Of $25.5M For The Exclusive Right

By Benzinga Newsdesk

April 11, 8:07 AM

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor

HRMY

4 minute read

Analyst Ratings

Evaluating Harmony Biosciences: Insights From 8 Financial Analysts

By Benzinga Insights

March 28, 12:00 PM

Harmony Biosciences (NASDAQ:HRMY) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from…

HRMY

2 minute read

Harmony Biosciences Sees 2024 Net Product Revenue Projected Between $700M-$720M; $50M Common Stock Repurchase In Q4 Bringing 2023 Total To $100M; Expect To Continue Opportunistic Share Repurchases In 2024

By Benzinga Newsdesk

January 8, 9:34 AM

2024 Key PrioritiesContinued Strong Growth for WAKIX in Adult Narcolepsy Drive commercial strategy to achieve Net Revenue >$700 million

HRMY

3 minute read

Analyst Ratings

A Glimpse Into The Expert Outlook On Harmony Biosciences Through 6 Analysts

By Benzinga Insights

January 2, 10:01 AM

Throughout the last three months, 6 analysts have evaluated Harmony Biosciences (NASDAQ:HRMY), offering a diverse set of opinions…

HRMY

4 minute read

Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

October 31, 1:36 PM

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment.

AIRE

2 minute read

Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday

By Lisa Levin

October 31, 12:04 PM

U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.

ANET

11 minute read

Earnings

Earnings Scheduled For October 31, 2023

By Benzinga Insights

October 31, 5:44 AM

Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third quarter. • BP (NYSE:BP) is expected to report quarterly earnings at $1.37 per share on revenue of $57.71 billion.

ABEV